Levetiracetam in toxic seizures

References

• Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology. 1989;39:1037–1039.
   PubMed Web of Science ®Google Scholar
• Alldredge BK, Lowenstein DH. Status epilepticus related to alcohol abuse. Epilepsia. 1993;34:1033–1037.
   PubMed Web of Science ®Google Scholar
• Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43:483–488.
   PubMed Web of Science ®Google Scholar
• Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med. 2002;22:235–239.
   PubMed Web of Science ®Google Scholar
• Lowenstein DH. Status epilepticus: an overview of the clinical problem. Epilepsia. 1999;40:S3–S8.
   PubMed Web of Science ®Google Scholar
• Cheng JY. Latency to treatment of status epilepticus is associated with mortality and functional status. J Neurol Sci. 2016;370:290–295.
   PubMed Web of Science ®Google Scholar
• DeLorenzo RJ, Garnett LK, Towne AR, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia. 1999;40:164–169.
   PubMed Web of Science ®Google Scholar
• Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5:246–256.
   PubMed Web of Science ®Google Scholar
• Jagoda A, Riggio S. Refractory status epilepticus in adults. Ann Emerg Med. 1993;22:1337–1348.
   PubMed Web of Science ®Google Scholar
• DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029–1035.
   PubMed Web of Science ®Google Scholar
• Thundiyil JG, Rowley F, Papa L, et al. Risk factors for complications of drug-induced seizures. J Med Toxicol. 2011;7:16–23.
   PubMedGoogle Scholar
• Lui HK, Hui KF, Fong WC, et al. De novo status epilepticus is associated with adverse outcome: an 11-year retrospective study in Hong Kong. Seizure. 2016;40:42–45.
   PubMed Web of Science ®Google Scholar
• Alvarez V, Drislane FW. Is favorable outcome possible after prolonged refractory status epilepticus? J Clin Neurophysiol. 2016;33:32–41.
   PubMed Web of Science ®Google Scholar
• Foreman B, Hirsch LJ. Epilepsy emergencies: diagnosis and management. Neurol Clin. 2012;30:11–41, vii.
   PubMed Web of Science ®Google Scholar
• Shah AS, Eddleston M. Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures? Clin Toxicol. 2010;48:800–805.
   PubMed Web of Science ®Google Scholar
• Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol. 2016;81:412–419.
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861–9866.
   PubMed Web of Science ®Google Scholar
• Rüegg S, Naegelin Y, Hardmeier M, et al. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav. 2008;12:477–480.
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–724.
   PubMed Web of Science ®Google Scholar
• Brophy GM, Bell R, Claassen J, Neurocritical Care Society Status Epilepticus Guideline Writing Committee, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23.
   PubMed Web of Science ®Google Scholar
• Al-Mufti F, Claassen J. Neurocritical care: status epilepticus review. Crit Care Clin. 2014;30: 751–764.
   PubMed Web of Science ®Google Scholar
• Cantrell FL, Wardi G, O'Connell C. Propofol use for toxin-related seizures. Pharmacotherapy. 2016;36:702–704.
   PubMed Web of Science ®Google Scholar
• Parviainen I, Kälviäinen R, Ruokonen E. Propofol and barbiturates for the anesthesia of refractory convulsive status epilepticus: pros and cons. Neurol Res. 2007;29:667–671.
   PubMed Web of Science ®Google Scholar
• Hassanian-Moghaddam H, Ghadiri F, Shojaei M, et al. Phenobarbital overdose presenting with status epilepticus: a case report. Seizure. 2016;40:57–58.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Hamano S, Oritsu T, et al. Effectiveness and safety of non-intravenous high-dose phenobarbital therapy for intractable epilepsy during childhood. Brain Dev. 2011;33:379–383.
   PubMed Web of Science ®Google Scholar
• Lützen L, Poulsen LM, Ulrichsen J. [Respiratory depression in delirium tremens patients treated with phenobarbital. A retrospective study]. Ugeskr Laeger. 2008;170:2018–2022.
   PubMedGoogle Scholar
• Callaham M, Schumaker H, Pentel P. Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning. J Pharmacol Exp Ther. 1988;245:216–220.
   PubMed Web of Science ®Google Scholar
• Osorio R, Burnstine B, Remler R, et al. Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients. Epilepsia. 1989;30:230–240.
   PubMed Web of Science ®Google Scholar
• Chua HC, Venketasubramanian N, Tan CB, et al. Paradoxical seizures in phenytoin toxicity. Singapore Med J. 1999;40:276–277.
   PubMedGoogle Scholar
• Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15:210–218.
   PubMed Web of Science ®Google Scholar
• Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695–714.
   PubMed Web of Science ®Google Scholar
• Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46:1323–1338.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Schmitz-Buhl M. Signs and symptoms of carbamazepine overdose. J Neurol. 1995;242:169–173.
   PubMed Web of Science ®Google Scholar
• Megarbane B, Leprince P, Deye N, et al. Extracorporeal life support in a case of acute carbamazepine poisoning with life-threatening refractory myocardial failure. Intensive Care Med. 2006;32:1409–1413.
   PubMed Web of Science ®Google Scholar
• Trinka E, Hofler J, Leitinger M, et al. Pharmacotherapy for Status Epilepticus. Drugs 2015;75:1499–1521.
   PubMed Web of Science ®Google Scholar
• Grover EH, Nazzal Y, Hirsch LJ. Treatment of Convulsive Status Epilepticus. Curr Treat Options Neurol. 2016;18:11.
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259:645–648.
   PubMed Web of Science ®Google Scholar
• Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia. 2007;48:1861–1869.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Prezioso G, Di Sabatino F, et al. The adverse event profile of levetiracetam: a meta-analysis on children and adults. Seizure. 2015;31:49–55.
   PubMed Web of Science ®Google Scholar